INTRODUCTION
The progressive degeneration of neurons underlies a range of diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), for which there are no disease-modifying treatments. Although recent advances in human genetics have identified causative factors in neurodegenerative disease (1, 2) , the pathways induced within neurons in response to these triggers are still poorly understood. Furthermore, most clinical cases of ALS and AD are sporadic, with no clear definable cause. A better understanding of how neurons respond to chronic stress may reveal common links between neurodegenerative diseases and suggest therapeutic avenues to modify disease progression regardless of the initial insult.
Recent work has identified the neuron-enriched kinase dual leucine zipper kinase (DLK) as an integrator of many types of neuronal injury, suggesting that this kinase may be a conserved driver of neuronal degeneration (3) (4) (5) (6) (7) (8) . DLK is required for initiation of the c-Jun N-terminal kinase (JNK)-dependent stress response in neurons and broadly regulates injury-induced transcriptional changes (3, 5) . Neurons lacking DLK expression are protected against axon degeneration and neuronal apoptosis, both during healthy development and in response to diverse neuronal insults (3) (4) (5) (6) (7) (8) . DLK also supports regeneration in invertebrate models and in permissive environments in mouse, such as peripheral nerve injury (5, (9) (10) (11) (12) . In all of these scenarios, DLK functions as an injury sensor that regulates the neuronal stress response, with the adoption of proapoptotic and proregenerative outcomes depending on the specific cellular context (5) . The central role of DLK in response to neuronal injury suggests that pharmacological inhibition of this kinase may be beneficial in chronic neurodegenerative disease, but this has yet to be tested experimentally in progressive disease models.
Inhibition of JNK pathway signaling downstream of DLK has been shown to slow neuronal degeneration in some contexts (13) , but it has proved challenging to generate brain-penetrant compounds that safely and effectively target specific JNK isoforms (14) . DLK inhibition may have similar benefits, and the development of selective, brain-penetrant DLK inhibitors suggests that it represents a more tractable therapeutic target (15, 16) . Here, we demonstrate that loss or inhibition of DLK signaling rapidly reversed the neuronal stress response in several chronic neurodegenerative disease models even if initiated after disease onset. Halting this stress response prolonged neuronal survival, preserved synapses, and improved cognitive and motor function in mouse models of ALS and AD.
RESULTS
The JNK pathway is activated in central nervous system tissues from mouse models and patients with ALS or AD To ascertain whether activation of the DLK/JNK pathway contributes to chronic neurodegenerative disease, we first examined whether aberrant JNK signaling occurs in the context of progressive neurodegeneration. Phosphorylation of both JNK and the downstream target c-Jun was examined, with a particular focus on phosphorylated c-Jun (p-c-Jun) because it is a specific marker of stress-induced JNK activity in neurons (4, 5, (17) (18) (19) (20) . In the SOD1 G93A transgenic mouse model of familial ALS (21, 22) , we found an age-dependent increase in p-c-Jun-positive cells in lumbar spinal cord of SOD1 G93A transgenic mice between 9 and 14 weeks of age, with little staining in nontransgenic (nonTg) littermate controls (Fig. 1, A and B) , consistent with previous reports (17, 18) . Costaining for the neuronal marker NeuN (Fig. 1C) revealed that p-c-Jun staining was almost entirely neuronal, with 94 of 100 p-cJun-positive cells also expressing NeuN ( fig. S2F ). Moreover, p-c-Jun costained with choline acetyltransferase (ChAT)-positive motor neurons, which are susceptible to death in this ALS disease mouse model ( fig. S1A ). Dlk mRNA localized to cells expressing the pan-neuronal marker Tubb3 (Fig. 1D and fig. S1B ) and the motor neuron marker Chat ( fig. S1C ), implying that DLK activity could be driving the phosphorylation of c-Jun in neurons. The number of p-c-Jun-positive cells was also increased in the cortex of a second ALS model, the TDP-43 A315T transgenic mouse (Fig. 1 , H and I) (23) . Many components of the JNK signaling pathway, including phosphorylated JNK (p-JNK), p-cJun, total JNK, and total c-Jun, were increased in lumbar spinal cord lysates from patients with sporadic ALS (Fig. 1 , E to G), suggesting that activation of the JNK pathway occurs in the human disease and is not limited to ALS caused by SOD1 mutations.
JNK pathway activity was also elevated in two transgenic mouse strains that model specific aspects of AD, PS2APP and Tau P301L (24) (25) (26) , at ages greater than 6 months ( , E and F), indicating that the aberrant JNK pathway activity was similarly limited to neurons in these models. In postmortem central nervous system (CNS) tissues from patients with either early-stage AD or confirmed AD, p-c-Jun immunostaining was significantly elevated in hippocampal neurons (Fig. 2 , E and F; P < 0.01), consistent with previous findings (27, 28) . To determine whether the presence of aberrant JNK activity correlated with the extent of disease pathology, we examined p-c-Jun, total c-Jun, and p-JNK in control, early-stage AD, and confirmed AD patient superior frontal gyrus, a brain region affected predominantly in the later stages of AD (29) . In these samples, increased JNK activity was observed only in confirmed AD but not in early AD postmortem brain samples (Fig. 2, G to I) . Expression of p-JNK and p-c-Jun in these samples correlated well with the presence of phosphorylated pathogenic Tau (pS202 and pS396/S404) (Fig. 2, G to I and fig. S2 , G and H), suggesting that stress-induced JNK activation occurs specifically in brain regions where disease pathology is present.
Loss of DLK reduces JNK activity in animal models of neurodegenerative disease During development or after acute neuronal injury, DLK is required for stress-induced JNK pathway activation and phosphorylation of c-Jun in neurons (3) (4) (5) 10 In the PS2APP and Tau P301L mice, tamoxifen treatment was initiated at~10 weeks of age and brain tissues were collected at 9 months of age, after significant AD-related pathology had developed. Deletion of Dlk reduced cortical DLK protein in both PS2APP;DLK cKO and Tau P301L ;DLK cKO mice (~75 to 81%; Fig. 3 , C, D, G, and H; P < 0.0001). This reduction in DLK expression was sufficient to significantly reduce cortical p-c-Jun (~41 to 48%) and total c-Jun (~30%; Fig. 3, C , D, G, and H; P < 0.0001) by Western blotting in both PS2APP;DLK cKO and Tau   P301L ;DLK cKO mice. The reduction in total c-Jun aligned with the previous finding that inhibition of c-Jun phosphorylation reduces total c-Jun expression (30) . To confirm that the reductions in p-c-Jun resulted from reduced DLK pathway activation, we measured the activity of two upstream components of the DLK/JNK pathway, MKK4 (mitogenactivated protein kinase kinase 4) and JNK. Because neurons display high basal activation of JNK and MKK4 that is not stress-dependent or affected by DLK (4), less robust changes were observed in these pathway markers after Dlk deletion. Small but significant reductions in p-JNK (~11 to 18%) were observed in both models [ Fig. 3 , D (P < 0.05) and H (P < 0.01)], whereas phosphorylated MKK4 (p-MKK4) was reduced in PS2APP;DLK cKO mice by~30% but was unchanged in Tau ;DLK cKO mice (by 45%; Fig. 3 , E, F, I, and J; P < 0.0001). Together, these results demonstrate that loss of DLK reduced stress-induced activation of the JNK pathway in three independent animal models of chronic neurodegenerative disease.
Loss of DLK is neuroprotective in SOD1
G93A transgenic mice We next examined the impact of DLK removal on motor neuron survival by comparing the number of spinal cord motor neurons at 14 weeks of age in SOD1
G93A
;DLK WT mice versus SOD1
;DLK cKO mice. Whereas SOD1 G93A mice with normal DLK expression showed the expected 40% loss of ChAT-positive neurons compared to nonTg littermates, the SOD1
;DLK cKO mice only lost 13% of ChAT-positive cells (Fig. 4 , A and B; P < 0.001). To determine whether motor neuron axons were also protected in SOD1
;DLK cKO mice, we examined total axonal lumen area in cross sections of sciatic nerve. On the basis of the progression of axon degeneration pathology in SOD1 G93A mice (31) , this end point provided the most robust measure at this age (14 weeks), because a significant decrease in axon number has not yet occurred ( fig. S3B ). Consistent with previous reports, axonal lumen area was decreased in SOD1 G93A mice, corresponding to the initial phase of axon degeneration (Fig. 4 , C and D; P < 0.001). A significant rescue in axonal lumen area was observed in SOD1
;DLK cKO mice (Fig. 4 , C and D), suggesting that Dlk deletion was sufficient to elicit axonal protection. SOD1
;DLK cKO animals also showed significant reductions in both ionized calcium binding adaptor molecule 1 (Iba1)-positive microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes (Fig. 4, E and F, and fig. S3 , C and D; P < 0.0001 and P < 0.01, respectively). Because DLK expression is enriched in neurons compared to glia (Fig. 1D and fig. S1B ) (32) , the reduction in microglial and astrocytic activation suggested that unhealthy neurons may be able to stimulate gliosis. transgenic and nonTg littermates. *P < 0.05, two-tailed Student's t test. Tau   P301L ;DLK cKO (n = 17) compared to Tau P301L ;DLK WT mice (n = 14). *P < 0.05, **P < 0.01, and ****P < 0.0001, twotailed Student's t test (F and I). ;DLK WT (black), n = 21 (with none being censored). Log-rank test (*P = 0.0085) for the whole model, with a significant DLK genotype effect (**P = 0.0028); sex effect (not significant 
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To determine whether the protection of motor neurons after Dlk deletion would provide lasting functional benefit, we examined symptom progression and life span in an independent cohort of SOD1 (34) , including the wire hang test, a measure of motor strength (Fig. 4H and fig. S3G ). Dlk deletion was well tolerated, with only minor reductions in body weights ( fig. S3, H and I ).
Dlk deletion is beneficial in two mouse models of AD In AD, reductions in dendritic spine densities are greatest within close proximity to amyloid plaques (35) , which can be recapitulated in mouse models (24, (36) (37) (38) (39) . On the basis of previous work, this end point can serve as an indicator of synaptic loss and provides a valuable measure of degenerative processes because neuronal loss is not a common feature of amyloid precursor protein (APP) transgenic mouse models of AD (40, 41) . Because DLK is present in the postsynaptic density and mediates neuronal degeneration after excitotoxic injury (4), we sought to determine whether plaque-associated synaptic loss is DLK-dependent through measurement of synaptic spine densities after selective deletion of Dlk from individual layer II/III neurons (4). Ex vivo imaging found 30% less spine loss proximal to plaques in PS2APP;DLK null neurons compared with PS2APP;DLK wild-type neurons (Fig. 5, A and B), indicating that Ab/plaque-associated synaptic loss is at least in part mediated by DLK signaling.
Because loss of synaptic spines is associated with cognitive decline both in human AD patients and in some animal models of AD (24, 36-39, 42, 43) , we next compared cognitive function in >7-month-old PS2APP mice, in which Dlk deletion was induced at 10 to 12 weeks of age. PS2APP mice with intact DLK showed impairment in acquisition of active avoidance behavior (Fig. 5C) (24, 36) . However, loss of DLK expression resulted in a complete rescue of the PS2APP phenotype, with the PS2APP;DLK cKO mice performing equally as well as nonTg controls on this task ( Fig. 5C ; P < 0.001). Spatial learning and memory were assessed in the Morris water maze, but no significant PS2APP transgenedependent differences were found in this cohort of mice such that assessment of DLK function was not possible (fig. S5A ). Fear-conditioning acquisition and 24-hour context fear memory were also not significantly different in PS2APP mice compared to nonTg controls ( fig. S5, C to F) . However, an increased freezing response to an audible tone (cued memory) was detected in PS2APP;DLK WT animals, which was rescued in PS2APP;DLK cKO mice ( fig. S5, G and H ). These results demonstrate that deletion of Dlk in young mice results in rescue of certain behavioral phenotypes in PS2APP mice. To determine whether DLK removal would have similar benefits after initiation of Ab/plaque deposition and associated JNK/DLK pathway activation, we deleted Dlk at 6 months of age in an independent cohort of PS2APP;DLK cKO mice ( fig. S6A ). These mice showed improvement in the active avoidance learning test ( Fig. 5D ; P < 0.01), suggesting that loss of DLK even subsequent to activation of the DLK/JNK pathway may be sufficient to reverse cognitive deficits in this task.
We next examined whether loss of DLK resulted in altered Ab/ plaque pathology in the PS2APP mice. Although synaptic spine density and cognitive function were improved after Dlk deletion, Ab42 production and plaque load were not reduced ( fig. S6) . At older ages, PS2APP; DLK cKO mice had slightly higher levels of full-length APP, amyloid plaques, and plaque-associated gliosis ( fig. S6, B to K) . These increases were not a result of altered b-secretase 1 (BACE1) ( fig. S6 , E and F) but could be explained by an aberrant up-regulation of hAPP expression driven by the Thy1 (thymus cell antigen 1) promoter ( fig. S6 , E to G). This observation was consistent with the previous finding that stressinduced Thy1 down-regulation is prevented in DLK cKO mice (5), suggesting that the increase in plaque pathology was specific to this mouse model. APP expression changes in the PS2APP;DLK cKO mice were specific to the Thy1-driven hAPP gene, whereas mAPP and prion protein (PrP) promoter-driven expression of hPS2 were unaffected ( fig. S6, E to G) .
To provide a second measure of AD-related neurodegeneration in a model that displays more robust cell loss, we also assessed DLK function in Tau P301L mice. The amount of total and phosphorylated Tau (p-Tau) was unchanged at 15 months of age ( fig. S7, A and B) , suggesting that loss of DLK did not alter Tau pathology. We found a significant attenuation of cell loss in the subiculum of Tau   P301L ;DLK cKO mice (Fig. 5 , E and F; P < 0.05), a brain area that develops Tau pathology (44) . Collectively, the results from these three independent models of chronic neurodegenerative disease demonstrate that Dlk deletion, even after disease onset, results in increased neuronal survival, enhanced synaptic integrity, and some functional benefits.
Treatment with DLK inhibitors is neuroprotective and can reverse injury-induced changes in gene expression
Before examining the activity of two structurally distinct DLK inhibitors, GNE-8505 ( fig. S8 ) and GNE-3511 (15), in chronic neurodegenerative disease mouse models, we first sought to better characterize the in vivo activity of these compounds using an acute optic nerve crush model where genetic deletion of Dlk or DLK inhibition before crush injury reduced injury-induced phosphorylation of c-Jun (15, 16) . To determine whether DLK inhibitors reduced p-c-Jun when administered after injury, we gave the animals a single dose of GNE-8505 18 hours after optic nerve crush, and we measured the amount of p-c-Jun in mouse retina at several time points. A single oral dose of GNE-8505 rapidly reduced p-c-Jun in a dose-dependent fashion within 1 hour, a decrease that was sustained for at least 6 hours (Fig. 6A) . p-c-Jun repression correlated with the plasma concentration of GNE-8505, allowing all time points to be pooled to generate an in vivo dose-response curve (Fig. 6B) . The calculated in vivo half maximal inhibitory concentration (IC 50 ) value of 0.98 ± 0.11 mM was consistent with the cellular IC 50 for this compound when corrected for protein binding (table S2) and suggested that continuous DLK activity was required to maintain c-Jun phosphorylation (and, conversely, that repressing p-c-Jun would require sustained DLK inhibition).
Previous microarray studies in DLK cKO mice revealed that DLK signaling not only regulates c-Jun phosphorylation but is also required for most of the injury-induced transcriptional changes after optic nerve crush (5). To determine whether DLK inhibition has the same effect, we gave the animals two doses of GNE-3511, starting at 3 days after nerve crush, and we assessed DLK-dependent gene expression by RNA sequencing (RNA-seq). As observed in previous studies (5), optic nerve injury induced numerous gene expression changes in vehicle-treated animals 3 days after injury. Just 12 hours of GNE-3511 treatment was sufficient to attenuate many of the injury-induced gene expression changes, with 148 up-regulated and 105 down-regulated genes demonstrating DLK dependence ( Fig. 6C ; P < 0.05). The DLK dependence of eight representative stress-induced genes, including Sprr1a, Atf3, Ddit3, and Bbc3, was then confirmed in a distinct cohort of animals ( fig. S9) . To determine whether the reversal of injury-induced DLK signaling was sufficient to elicit neuroprotection in the mouse retina, we administered GNE-3511 twice daily for 3 days starting at 18 hours after optic nerve crush. Treatment with DLK inhibitors resulted in a significant reduction in retinal ganglion cell (RGC) apoptosis (by 96%; P = 0.0014) and maintenance of Brn3 expression (by 50%; P < 0.0001) in RGCs 3 days after crush injury (Fig. 6, D to F) . This demonstrated that inhibition of DLK resulted in neuroprotection similar to that seen in DLK cKO animals even when dosing was initiated after injury (5).
DLK inhibition is beneficial in a mouse model of ALS
We next sought to determine whether pharmacological inhibition of DLK could have beneficial effects in a chronic neurodegenerative disease mouse model. These studies focused largely on the SOD1 G93A transgenic mouse model of ALS where degeneration of motor neurons and loss of neuromuscular junctions are characteristic of the disease and can be readily monitored. We first tested whether short-term DLK inhibition was sufficient to reverse existing DLK/JNK signaling in vivo. GNE-3511 treatment reduced the number of p-c-Jun-positive cells in a dosedependent manner in the spinal cords of 14-week-old SOD1 G93A mice when compared with vehicle-treated animals (Fig. 7, A to C) . Similar results were obtained with GNE-8505 treatment (Fig. 7B) , confirming that this effect was a result of DLK inhibition. Furthermore, a single dose of GNE-8505 was sufficient to elicit a comparable dosedependent reduction in brain p-c-Jun at 6 hours after dose in both PS2APP and Tau P301L mice, suggesting that this observation was not specific to the SOD1 G93A mouse model ( fig. S10 ). Thus, acute treatment of mid-disease stage animals with DLK inhibitors reduced activity in the DLK/JNK signaling pathway and decreased p-c-Jun even when disease-related JNK signaling had been present for weeks before drug treatment.
To determine whether DLK inhibitor treatment was able to protect motor neurons from degeneration, we first treated cultured mouse embryonic stem cell-derived HB9-GFP (HB9-green fluorescent protein)-positive motor neurons with GNE-3511 after trophic factor withdrawal. A dose-dependent increase in motor neuron survival was observed at 24 hours after addition of the compound (Fig. 7, D and E) . We then examined whether chronic GNE-3511 treatment was able to slow disease progression in SOD1 G93A mice. In an effort to design a feasible preclinical study in which the SOD1 G93A mice were receiving adequate dosing while minimizing dosing-related stress, we opted to administer GNE-3511 in food and assessed an early measure of disease progression, neuromuscular junction loss. Loss of innervation of the neuromuscular junctions in gastrocnemius muscle is one of the first signs of disease in this model (45, 46) , with more than 50% of neuromuscular junctions showing complete denervation by 9 weeks of age. Notably, GNE-3511 treatment delayed neuromuscular junction denervation by~10% (Fig. 7, F to H, and fig. S11 ; P = 0.0094) compared to vehicle-treated SOD1 G93A mice, demonstrating that chronic inhibition of DLK between 5 and 9 weeks of age was able to provide neuroprotection in this mouse model of ALS.
DISCUSSION
Here, we demonstrate that either genetic deletion or pharmacological inhibition of DLK is sufficient to reduce disease-associated JNK pathway activation and provide functional neuroprotection in mouse models of ALS and AD. The function of DLK signaling described here is consistent with reports examining DLK function after acute insults, such as axonal injury, excitotoxic insult, and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treatment (3-5, 15, 47) , suggesting that DLK represents a conserved component of the neuronal stress response that is downstream of a variety of insults. This, along with the observation that similar JNK pathway activation exists in the CNS of patients with ALS and AD, supports the hypothesis that DLK signaling contributes to neuronal degeneration and subsequent functional decline in a range of neurodegenerative diseases.
The number of p-c-Jun-positive neurons present in the SOD1 G93A mouse model of ALS was considerably higher than the number expected to be undergoing apoptosis at any given time (18) . In addition, widespread p-c-Jun-positive cells are present in PS2APP mice, although extensive neuronal loss does not occur in this AD mouse model (40, 41) . These observations suggest that DLK activation may not lead directly to apoptosis. Instead, neurons appear to undergo an extended period of stress, suggesting that DLK/JNK signaling may also contribute to degeneration of neuronal processes and synapse loss. The rescue of synaptic spines in PS2APP mice via Dlk deletion provides a direct demonstration that loss of this prodegenerative signal protects against subapoptotic cellular damage. Last, the cognitive improvements observed in PS2APP mice after late Dlk deletion argues that meaningful functional benefit can be achieved by halting existing neuronal DLK/JNK signaling. These observations along with the rapid reversal of c-Jun phosphorylation and stress-induced transcriptional changes within hours of a single DLK inhibitor treatment argue that individual neurons can still be rescued from degeneration after DLK/JNK pathway activation. Data from multiple studies indicate that some adaptive/proregenerative stress responses may also take place in p-c-Jun-positive neurons (5, 9-12), yet the functional benefits observed in DLK cKO animals argue that loss of DLK signaling provides a net benefit in the context of chronic neurodegeneration.
Nonetheless, important questions must still be answered to accurately assess the therapeutic potential of this approach. First, although the histological protection of neurons in DLK cKO mice was robust across models, it is challenging to determine whether the effect size observed in the functional end points measured would be likely to translate to clinical benefit. Second, additional studies are needed to determine the level of DLK inhibition required to maintain efficacy after chronic drug treatment and to confirm that these doses will be tolerated. Although encouraging progress has been made toward the development of selective brain-penetrant DLK inhibitors (15, 16) , it has historically proved challenging to design kinase inhibitors that are well tolerated in clinical studies.
There are a number of considerations, however, that make targeting DLK more attractive than other approaches aimed at inhibition of JNK signaling. First, DLK expression is enriched in neurons and specifically regulates stress-induced JNK signaling (32, 48, 49) , providing a specific means to target neuronal dysfunction in CNS disease, in contrast to many other components of the JNK signaling pathway (32) . Second, loss of DLK signaling in the adult is well tolerated (4) . Third, given the broad regulation of the transcriptional stress response in neurons via DLK signaling and the ability of DLK inhibitors to rapidly reverse injury-induced gene expression changes (Fig. 6) , DLK inhibitor treatment could potentially attenuate a range of downstream signaling events in the context of progressive degeneration (5) . Given the consistent role for DLK/JNK signaling in multiple disease models driven by diverse mechanisms, DLK inhibitors hold broad therapeutic potential and may warrant advancement to clinical studies should safe compounds be identified. 
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Study design
The primary research objectives of this study were to assess whether mouse models of neurodegeneration (including SOD1   G93A , PS2APP, and Tau P301L mice) and CNS tissue from patients with ALS and AD display evidence of increased DLK pathway activity and to test whether genetic deletion or pharmacological inhibition of DLK could ameliorate end points of disease progression. In all experiments, animals were randomly assigned to experimental or treatment groups and matched for age, sex, and littermate controls. All behavioral scorings and histological analyses were carried out blind to genotype and treatment groups. Any SOD1
G93A transgenic mouse with a reduced transgene copy number was excluded ( fig. S4 ). All animal studies were authorized and approved by the Genentech Institutional Animal Care and Use Committee. Human samples were procured with Ethics Committee approval and written informed consent.
Mice ALS mouse models used in this work were the SOD1 G93A high-copy number transgenic mice (SOD1) originally derived from the Jackson Laboratory [JAX stock #002726 (21)] and backcrossed for at least 10 generations into C57BL/6N (Charles River Laboratories) and TDP-43 A315T (JAX #010700) (23) . Treatment groups for all experiments using SOD1 mice were balanced for gender and litter, and all mice were genotyped for SOD1 copy number ( fig. S4 and table S1 ). AD mouse models used in this study included PS2APP mice that coexpress human APP (hAPP) with the Swedish mutation K670N/ M671L and human presenilin 2 with the N141I mutation, driven by Thy1 and PrP promoters, respectively (25) . Tau P301L mice overexpress mutant human Tau with the P301L mutation (26) driven by the Thy1 promoter. The PS2APP and Tau alleles in each line were bred to homozygosity for all mice used in this study.
Inducible DLK knockout mice were described previously (4 ;DLK cKO , respectively, after recombination. Dlk excision was achieved by placing the mice on a tamoxifen-containing diet (about 40 mg/kg per day) for 3 weeks to induce Cre-mediated DNA recombination. This protocol was found to generate maximal recombination efficiency of the Dlk allele in the CNS while minimizing the loss of animals due to tamoxifen toxicity. All mice in this study were placed on this diet, including nonTg controls, where applicable. SOD1 G93A mice were placed on the diet at 28 days of age and PS2APP and Tau P301L mice at 10 to 12 weeks of age or 6 months of age. While on medicated chow, all mice appeared healthy and active overall despite modest weight loss (up to 10 to 15%). All mice were returned to regular chow diet after the tamoxifen treatment.
Human postmortem samples for Western blotting and immunohistochemistry
Frozen spinal cord tissues were procured from patients with sporadic ALS and control subjects with no known neurodegenerative diseases. These cases were clinically and neuropathologically evaluated at the University of California, San Francisco. Additional human tissue specimens were provided by the Department of Veterans Affairs Repository. Human frozen brain samples were procured from patients with putative AD (early-stage AD) or confirmed AD along with age-matched controls from Folio Biosciences or Banner Sun Health Research Institute. All human tissues were collected with informed consents and institutional review board approvals.
Tissue harvest and preparation SOD1 mice were anesthetized with 2.5% tribromoethanol (0.5 ml/25 g body weight) and transcardially exsanguinated with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS for fixation. Gastrocnemius muscles were collected and cryoprotected in 30% sucrose. Sciatic nerve was harvested 2 to 3 cm proximal to the branch point of the tibial, peroneal, and sural nerves and postfixed in 4% PFA overnight. Spinal cords were harvested as previously described and postfixed in 4% PFA overnight, then transferred to PBS, and shipped to NeuroScience Associates for histology.
At indicated time points, PS2APP and Tau P301L on DLK WT or DLK cKO background animals were deeply anesthetized and PBS-perfused. After PBS perfusion, the brain was collected, and the left hippocampus and cortex were frozen and later homogenized for Western blotting (see Supplementary Materials and Methods). The right forebrain was dropfixed in 4% PFA for 48-hour shaking at 4°C, then cryoprotected in 30% sucrose, and sectioned sagittally at 35 mm using a sliding microtome. Sections were preserved in cryoprotectant (30% glycerol, 30% ethylene glycol, and PBS) and stored at −20°C.
Immunohistochemical staining
Spinal cord histology and staining Lumbar spinal cord segments were sectioned and sampled as previously described (45) . They were multiply embedded into a gelatin matrix using MultiBrain Technology (NeuroScience Associates). Each MultiBrain block was sectioned coronally at 25 mm. A series of 33 sections equally spaced at 300-mm intervals throughout the entire lumbar spinal cord was used for staining. Spinal cord sections were stained as previously described (45) . Immunohistochemical staining was performed using goat anti-ChAT (Millipore AB144P), rabbit anti-GFAP (Dako Z0334), rabbit anti-Iba1 (Wako 019-19741), rabbit anti-p-c-Jun (Ser   63   ) II (Cell Signaling #9261), and mouse anti-NeuN (clone A60, Millipore MAB377). Brain histology and staining Free-floating sections (35 mm thick) were rinsed in PBS then PBS with 0.1% Triton X (PBST), treated with 3% hydrogen peroxide in PBST, and blocked with 5% bovine serum albumin (BSA) in PBST before overnight incubation at 4°C, with primary antibody diluted in 1% BSA in PBST [anti-Iba1 (1:1000), anti-GFAP (1:1000), and antip-c-Jun (Ser 63 ) II (1:600)]. Binding was detected with biotin-conjugated secondary antibodies, followed by avidin-biotin-horseradish peroxidase (HRP) complex (details in VECTASTAIN Elite ABC kit; Vector Laboratories #PK6100), and developed with diaminobenzidine tetrahydrochloride.
For detection of p-c-Jun (Ser 63 ) in human AD and control tissue, immunohistochemistry was performed on 4-mm-thick formalin-fixed, paraffin-embedded tissue sections mounted on glass slides. Staining was performed on Dako Autostainer using Target Retrieval Solution (Dako) for antigen retrieval. Detection used goat anti-rabbit biotinylated secondary antibody (Vector Laboratories), followed by VECTASTAIN Elite ABC HRP kit (Vector Laboratories) and metal-enhanced diaminobenzidine visualization (Thermo Fisher Scientific). The sections were counterstained with hematoxylin, dehydrated, and coverslipped.
Statistical analysis
Statistical tests were performed using GraphPad Prism 6.0 software (GraphPad Software Inc.) or JMP 10.0.2 software (SAS Institute Inc.). All data are presented as means ± SEM, except when stated otherwise in the figure legends. Unless otherwise stated, for quantitative cell morphology (spine density), biochemical, and histological analysis, statistical significance was assessed by Student's t test for comparison between two samples or by one-way or two-way ANOVA with post hoc Tukey-Kramer honest significant difference test for comparison across multiple groups or Dunnett's test versus controls. Nonparametric tests included MannWhitney test or Kruskal-Wallis ANOVA followed by Dunn's multiplecomparison test. For behavioral data collected over multiple sessions or positions (that is, active avoidance), we used multifactor repeated-measures ANOVA with the between-subjects factor of genotype (PS2APP or DLK) and the within-subjects factor of sessions (sessions or trials). For survival analysis of the SOD1 mice, a log-rank test was assessed for the whole model, with examination of DLK genotype and sex effects.
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